CD8A and neoplasm: Taken together and in consistence with previous data, we identify a significant survival advantage and favourable histopathological features, such as absence of an EMT-type tumor budding, in PDAC patients with CD8+/FOXP3- phenotype, suggesting a close interaction of the immune cells with the molecular pathways that control the EMT process.